Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398207 | 1.00 | MGLL (0.42) | MGLLHSD17B10SLC6A7HCRTR1HCRTR2 | |
| SCHEMBL6371864 | 0.85 | GBA1 (0.46) | MGLLHSD17B10SLC6A7HCRTR1HCRTR2 | |
| SCHEMBL6468540 | 0.84 | HSD17B10 (0.48) | MGLLHSD17B10SLC6A7HCRTR1HCRTR2 | |
| SCHEMBL1257628 | 0.84 | HSD17B10 (0.48) | MGLLHSD17B10SLC6A7HCRTR1HCRTR2 | |
| SCHEMBL6467775 | 0.84 | GBA1 (0.44) | MGLLHSD17B10MAPTHSP90AA1POLB | |
| SCHEMBL1258661 | 0.84 | GBA1 (0.44) | MGLLHSD17B10MAPTHSP90AA1POLB | |
| SCHEMBL1256000 | 0.84 | SLC6A7 (0.56) | MGLLHSD17B10SLC6A7HCRTR1HCRTR2 | |
| SCHEMBL1257428 | 0.84 | SLC6A7 (0.56) | MGLLHSD17B10SLC6A7HCRTR1HCRTR2 | |
| SCHEMBL2401257 | 0.84 | SLC6A7 (0.56) | MGLLHSD17B10SLC6A7HCRTR1HCRTR2 | |
| SCHEMBL1258676 | 0.82 | MEN1 (0.59) | MGLLHRH3MAPTCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168788-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110237601-A1 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7880002-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880002-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237601-A1 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CCR2 | MGLL 3512/4885HSD17B10 3762/4885SLC6A7 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.